26 September 2017
LabCentral and Pfizer announced plans to open LabCentral 610, a new LabCentral offering located at Pfizer’s Kendall Square Worldwide Research and Development campus, Cambridge, Massachusetts, U.S. The facility is slated to open in December and will house up to six early- to mid-stage companies.
Eligible startups include those with high-impact science, excellent execution, and significant prospects for achieving scientific and business success whose space needs exceed current LabCentral offerings.
A joint steering committee made up of representatives from LabCentral and Pfizer evaluate potential companies. Three local biotechs have been accepted: Affinivax, EnBiotix, and Aquinnah Pharmaceuticals. Companies interested in applying can learn more on LabCentral’s website.
“As our resident startups have met their scientific milestones quickly and efficiently, they’ve thrived and grown – often citing LabCentral’s support and coworking model as a key factor,” said LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D.”
LabCentral developed the LabCentral 610 site in response to requests from resident startups outgrowing or “aging out” of its original facility who want to remain within LabCentral’s supportive environment as they continue on in their next stage of development.
Pfizer’s Chief Scientific Officer of Internal Medicine Morrie Birnbaum, M.D., Ph.D. commented, “Pfizer is proud to add LabCentral 610 to our growing Kendall Square Worldwide Research and Development campus. Collaborating with leaders such as LabCentral to foster scientific exchange and grow the next generation of biotechs is core to our mission, and it’s a testament to the strength of the area’s biomedical ecosystem to see these types of collaborations develop.”
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024